Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Combination of dalantercept plus axitinib versus placebo plus axitinib in advanced clear cell renal cell carcinoma

Dr Martin Voss - Memorial Sloan Kettering Cancer Centre, New York City, USA
Combination of dalantercept plus axitinib versus placebo plus axitinib in advanced clear cell renal cell carcinoma ( Dr Martin Voss - Memorial Sloan Kettering Cancer Centre, New York City, USA )
28 Feb 2015

Docetaxel with androgen deprivation therapy combo in hormone-naïve metastatic prostate cancer

Dr Gwenaëlle Gravis - Institut Paoli-Calmettes, Marseilles, France
Docetaxel with androgen deprivation therapy combo in hormone-naïve metastatic prostate cancer ( Dr Gwenaëlle Gravis - Institut Paoli-Calmettes, Marseilles, France )
28 Feb 2015

VEGF targeted therapy and chemo an active combination in rapidly progressive renal cell carcinoma

Dr Rana McKay - Dana-Farber Cancer Institute, Boston, USA
VEGF targeted therapy and chemo an active combination in rapidly progressive renal cell carcinoma ( Dr Rana McKay - Dana-Farber Cancer Institute, Boston, USA )
27 Feb 2015

Impact of statins on survival outcomes in metastatic renal cell carcinoma

Dr Rana McKay - Dana-Farber Cancer Institute, Boston, USA
Impact of statins on survival outcomes in metastatic renal cell carcinoma ( Dr Rana McKay - Dana-Farber Cancer Institute, Boston, USA )
27 Feb 2015

Genomic profiling may reveal new drug targets in urothelial carcinoma

Dr Jeffrey Ross - Albany Medical College, Albany, USA
Genomic profiling may reveal new drug targets in urothelial carcinoma ( Dr Jeffrey Ross - Albany Medical College, Albany, USA )
27 Feb 2015

Combination of abiraterone and cabazitaxel in metastatic castration-resistant prostate cancer

Dr Joaquin Mateo - Institute of Cancer Research, London, UK
Combination of abiraterone and cabazitaxel in metastatic castration-resistant prostate cancer ( Dr Joaquin Mateo - Institute of Cancer Research, London, UK )
27 Feb 2015

Management after radical prostatectomy: early adjuvant radiotherapy or wait-and-see?

Dr Mohammad Parvez Shaikh - Loyola University Medical Centre, Maywood, USA
Management after radical prostatectomy: early adjuvant radiotherapy or wait-and-see? ( Dr Mohammad Parvez Shaikh - Loyola University Medical Centre, Maywood, USA )
27 Feb 2015

Is there a role for androgen deprivation therapy combined with radiotherapy in intermediate risk prostate cancer?

Prof Abdenour Nabid - Sherbrooke University Hospital Centre, Sherbrooke, Canada
Is there a role for androgen deprivation therapy combined with radiotherapy in intermediate risk prostate cancer? ( Prof Abdenour Nabid - Sherbrooke University Hospital Centre, Sherbrooke, Canada )
27 Feb 2015

When and whether to conduct endocrine therapy in non-metastatic prostate cancer

Dr Frederik Birkebæk Thomsen - University of Copenhagen, Copenhagen, Denmark
When and whether to conduct endocrine therapy in non-metastatic prostate cancer ( Dr Frederik Birkebæk Thomsen - University of Copenhagen, Copenhagen, Denmark )
27 Feb 2015

High BMI beneficial in kidney cancer

Dr Laurence Albiges - Dana-Farber Cancer Institute, Boston, USA
High BMI beneficial in kidney cancer ( Dr Laurence Albiges - Dana-Farber Cancer Institute, Boston, USA )
27 Feb 2015

Basal subtype predicts clinical benefit from neoadjuvant chemo in urothelial cancer

Dr Arlene Siefker-Radtke - MD Anderson Cancer Centre, Houston, USA
Basal subtype predicts clinical benefit from neoadjuvant chemo in urothelial cancer ( Dr Arlene Siefker-Radtke - MD Anderson Cancer Centre, Houston, USA )
27 Feb 2015

New approach to prostate cancer screening

Dr Sanoj Punnen - University of Miami, Miami, USA
New approach to prostate cancer screening ( Dr Sanoj Punnen - University of Miami, Miami, USA )
27 Feb 2015